Neovasc to Participate at Upcoming Investor and Medical Conferences in February
VANCOUVER, Feb. 9, 2015 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company“) (NASDAQ: NVCN) (TSX: NVC) today announced that the Company will be participating at three upcoming conferences.
2015 Leerink Global Healthcare Conference
Waldorf Astoria, New York
Wednesday, February 11, 2015 at 10:40 am ET
Neovasc CEO Alexei Marko’s presentation at the Leerink Conference will provide an overview of the Company. A live webcast of the Company’s presentation at the conference will be available via a link provided at www.neovasc.com. After the presentation, a replay of the webcast will be available for 90 days at the Company website.
Joint Interventional Meeting (JIM 2015)
Ergife Palace Hotel, Rome
February 12 – 15
Company representatives will be in attendance to support activities related to the commercial launch of its Neovasc Reducer™ and the TIARA-I Early Feasibility study.
Cardiovascular Research Technologies (CRT)
Omni Shoreham Hotel, Washington DC
February 21 – 24, 2015
Vicki Bebeau, Vice President of Clinical and Regulatory Affairs for Neovasc will be participating in both the CRT Valve & Structural III session and the FDA Town Hall as a Speaker and Panel member in reference to the Neovasc Early Feasibility Study experience.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products in development include the Tiara™, for the transcatheter treatment of mitral valve disease and the Neovasc Reducer™ for the treatment of refractory angina. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.
Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; the potential benefits of the Neovasc Reducer™ and Tiara™; the Company’s receipt of any required local and institutional approvals, European enrollment and the success of applications in Europe; our anticipated use of proceeds from any financings, a history of losses and lack of and uncertainty of revenues, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company’s filings with Canadian securities regulators. No assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.
SOURCE Neovasc Inc.